Aim: To investigate the vasoactivity of calycosin, a major active component of Astragali Radix. Methods: Experiments were performed on isolated rat thoracic aortic rings pre-contracted with phenylephrine (PHE) or KCl. Results: Calycosin produced a concentration-dependent relaxation on the tissue pre-contracted using PHE with 4.46±0.13 of pD 2 and 95.85%±2.67% of E max ; or using KCl with 4.27±0.05 of pD 2 and 99.06%±2.15% of E max , and displaced downwards the concentration-response curves of aortic rings to PHE or KCl. The relaxant effect of calycosin on denuded endothelium aortic rings was the same as on intact endothelium aortic rings, and its vasorelaxant effect was not influenced by L-NAME or indomethacin. In Ca 2+ -free solution, calycosin (30 µmol/L) did not have an effect on PHE (1×10 -6 mol/L)-induced aortic ring contraction. The effects of calycosin and nifedipine where somewhat different; calycosin decreased aortic ring contractions induced by the two agonists, but nifedipine displayed a more potent inhibitory effect on KCl-induced contractions than on PHE-induced contractions, and the vascular relaxing effects of calycosin and nifidipine were additive on PHEinduced contraction but not KCl-induced. Conclusion: Calycosin is a vasorelaxant. Its action is endothelium-independent and is unrelated to intracellular Ca 2+ release. It is a noncompetitive Ca 2+ channel blocker. The effect of calycosin on Ca 2+ channel blockade may be different from that of dihydropyridines. This study demonstrated a novel pharmacological activity of calycosin, and supplied a theoretic foundation for Astragali Radix application.
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Introduction
Astragali Radix, the dry root of Astragalus membranceus (Fisch) Bge, known as Huangqi in China, has been used for centuries as a primary Chinese tonic herb [1] . It contains numerous triterpene saponins, polysaccharides, and flavonoids, which are known to have various biological effects. In modern Chinese medicine, Huangqi is widely used as an immune modulator. It is also used as an adjunctive therapy to chemotherapy and radiation therapy in cancer [2, 3] . Recently, a report was published on the vasorelaxation activities of Astragali Radix [4] . Calycosin, an isoflavonoid, is the major active component in Astragali Radix. It has been chosen as one of the marker compounds for the chemical evaluation or standardization of Astragali Radix and its products [5] . Calycosin displayed beneficial effects such as antitumor [6] , antioxidation [7] , anti-ischemia [8] , inhibition of hyperpermeability induced by low osmolarity [9] , scavenging free radicals and neuroprotective activity [10] . However, the effect of calycosin on vasoactivity has not been reported as yet. The purpose of the present study was to investigate the vasoactivity of calycosin and its mechanisms.
Materials and methods
Chemicals and reagents Calycosin (purity 99%) was prepared by Natural Medicinal Chemistry Department of Peking University. N w -nitro-L-arginine methyl ester (L-NAME) was the product of Sigma-Aldrich chemie Gmbh, Steinheim, Germany; phenylephrine (PHE) was purchased from Shanghai Harvest Pharmaceutical Co (Shanghai, China); indomethacin was the product of China Shijiazhuang Group Pharmaceutical Co; and nifedipine was the product of Tianjin Lisheng Pharmaceutical Co. All inorganic salts were purchased from Beijing Chemical Reagent.
Stock solutions of calycosin in Me 2 SO (0.1 mol/L) and nifedipine in 95% ethanol (9×10 -3 mol/L) were stored at -20 °C and used within one week. Indomethacin was dissolved in 95% ethanol before use. Nifedipine and indomethacin were shielded from light with aluminium foil. The highest concentrations of Me 2 SO and ethanol, which were 0.1% and 0.001%, respectively, did not affect the response of the aorta rings. The concentrations given are the final concentration in the bath chambers.
Animals Male Sprague-Dawley rats were obtained from the Experimental Animal Center of Peking University. The experimental procedures were approved by the Local Committee on Animal Care and Use.
Tissue preparation Rats weighing 250-300 g were anesthetized with 50 mg/kg sodium pentobarbital (ip) and killed by exsanguination from the carotid artery. The thoracic aorta was isolated and placed into cold Krebs' solution constantly aerated with 95% O 2 and 5% CO 2 , from where the aorta was cleaned of the fat and connective tissue and cut into 3-5 mm wide rings. The vessel preparations were mounted with one stainless steel wire in the organ bath, and the other wire through the vessel lumen was connected to a force transducer. Isometric tension change was recorded continuously on a two-channel physiological recorder (Chengdu Equipment Factory). The tissue was incubated in Krebs' solution (pH 7.4) at 37 ºC, bubbled with a 95% O 2 -5% CO 2 mixed gas. The Krebs' solution contained the following composition (in mmol/L): NaCl 120, KCl 5.5, MgCl 2 ·6H 2 O 1.2, NaH 2 PO 4 1.56, CaCl 2 2.5, NaHCO 3 20, D-glucose 10.1, EDTA 0.03. The experimental procedures were performed as described by Chen and Kwan [11] . KCl or PHE-induced contractions on endothelium-intact aortic rings To evaluate the effect of calycosin on the contractions of aortic rings, two different experimental protocols were used. In one protocol, after 60 min equilibration in Krebs' solution, aortic rings were precontracted with KCl (80 mmol/L) or PHE (1×10 -6 mol/L), and when the plateau was attained, calycosin (1×10 mol/L) were performed. Each ring was used for one determination.
PHE-induced contractions on endothelium-denuded arterial rings To investigate whether the relaxing response of calycosin depends on the endothelium, its effect was observed in endothelium-denuded arterial rings. Calycosin was added in a cumulative manner (1×10 -6 -1×10 -4 mol/L) during the tonic contraction phase induced by PHE (1×10 -6 mol/L). The endothelium was denuded from arterial rings by cannulating the forceps and gently rolling the vessel between the forceps and filter paper. The intactness or the denudation of endothelium was confirmed by the appearance or the disappearance of relaxant response to acetylcholine (10 µmol/L) in PHE (1×10 -6 mol/L) pre-contracted rings. Correlation of endothelial mediators and calycosin-induced relaxation To determine whether calycosin-produced relaxation was mediated by prostanoids or nitric oxide released from endothelial cells, endothelium-intact aortic rings were pre-incubated with the NO synthase inhibitor L-NAME 
Results

Effects of calycosin on aortic ring tension development
Calycosin up to 300 µmol/L had no effect on baseline tension in rat aortic rings. On arterial rings with endothelium, precontracted with PHE and KCl, calycosin (1×10
mol/L) produced a concentration-dependent and slowly developing relaxation. When pre-contracted with PHE, 100 µmol/L of calycosin produced a maximum relaxation up to 95.85%±2.67%, pD 2 was 4.46±0.13. When pre-contracted with KCl, 300 µmol·L -1 of calycosin produced a maximum relaxation up to 99.06%±2.15%, and pD 2 was 4.27±0.05 ( Figure 1A) .
Calycosin shifted cumulative concentration-response curves for PHE or KCl to right, and lowered their E max from 135.78%±3.21% to 109.77%±12.31% for PHE (P<0.05), and from 48.10±4.50 to35.30±3.7 mg/mm 2 for KCl (P<0.01). It also decreased their pD 2 from 7.62±0.04 to 7.51±0.05 for PHE (P<0. 05), and from 1.88±0.14 to 1.54±0.12 (P<0.01) for KCl ( Figure  1B and 1C) . These results indicate that the Ca 2+ antagonistic effects of calycosin were noncompetitive.
Effects of calycosin on rat aortic rings with or without endothelium To investigate whether calycosin-induced relaxation was endothelium dependent or not, experiments were performed in both endothelium-intact and -denuded aortic rings precontracted by PHE. The results showed that calycosin produced a concentration-dependent depression on PHE-induced contraction both in the endothelium-intact and in the endothelium-denuded aortic rings. The pD 2 values for the two cases were 4.46±0.13 and 4.46±0.20, respectively. Concentration-response curves for cumulative calycosin treatment showed no difference in differently treated arteries (Figure 2A ). It is suggested that the vascular relaxing effect of calycosin is independent from endothelium. release from the sarcoplasmic reticulum.
Effects of endothelial mediators on calycosin-induced vascular relaxation
Comparison of the inhibitory effects of calycosin and nifedipine on KCl-or PHE-induced contraction For the sake of comparison, the blockade of KCl or PHE induced contractions with 90 nmol/L of nifedipine was also observed. KCland PHE-induced contractions were all reduced by calycosin or by nifedipine (Figure 4, 5) . Despite the great concentration difference between the two agents, nifedipine displayed a more potent effect in blocking KCl-induced contraction than calycosin (calycosin: 29.9±9.2 mg/mm 2 ; nifedipine: 6.4±4.1 mg/mm 2 ). On the PHE-induced contraction, the reduction of tension produced by calycosin was similar to that by nifedipine (41.3±5.7 mg/mm 2 for calycosin and 40.8±7.5 mg/mm 2 for nifedipine). On PHE-induced contraction, the combined use of calycosin and nifedipine showed more potent inhibitory effect than either agent alone. On KCl-induced contraction, the combined use of the two agents showed more potent inhibitory effect than calycosin, and the effect of combined use of the two agents did not show change compared with nifedipine alone. 
Discussion
Calycosin has been evidenced to have various pharmacological effects [6] [7] [8] [9] [10] , and we have demonstrated its novel pharmacological activity (eg, vaso-relaxation) in this study. Calycosin produced concentration-dependent relaxation on rat thoracic aortic rings pre-contracted with PHE or KCl, indicating it inhibits voltage-operated Ca 2+ channels (VOC), it may also inhibit receptor-operated Ca 2+ channels (ROC), but further and sufficient evidence is needed. The pD 2 values for endothelium intact rings and endothelium-denuded rings were not different, and its effect on aortic contraction was not mediated by NO or PGI 2 . It is suggested that the inhibitory effect of calycosin on PHE-induced contraction was endothelium-independent, and the target of calycosin may be on vascular smooth muscle cells but not on endothelial cells. Smooth muscle contracts in response to the activation of voltage-dependent and receptor-operated Ca 2+ channels. Ca 2+ is also released from intracellular stores upon activation [12] . KCl depolarizes and opens VOC, leading to Ca 2+ influx, whilst PHE is able to open ROC to induce calcium influx in aorta without producing membrane depolarization [11, [13] [14] [15] . Calycosin significantly inhibited KCl-induced vasocontraction, and antagonized Ca 2+ -induced contraction in aortic rings exposed to KCl, suggesting that calycosin decreased extracellular Ca 2+ influx through VOC. Moreover, calycosin significantly inhibited PHE-induced contraction, indicating that it also decreased Ca 2+ influx through ROC. Receptor-agonists increase Ca 2+ sensitivity of contractile elements by activating the GTP-binding protein to make phosphatidylinositol turnover to generate inositol trisphosphate (IP 3 ), which releases Ca 2+ from intracellular storage sites [16, 17] . PHE-induced contraction in a Ca 2+ free medium should result only from Ca 2+ release from the intracellular store upon activation of IP 3 -sensitive Ca 2+ channels [18] . Calycosin had no influence on PHE-induced transient contraction in a Ca 2+ -free medium in this study, suggesting that the vasorelaxant effect of calycosin was not related to the sarcolemma Ca 2+ channels. It played a role through inhibit- ing extracellular Ca 2+ influx but not intracellular release, that is, it only blocked Ca 2+ channel on cell membrane but not on sarcolemma membrane. The inhibitory effect of calycosin on vasocontraction was compared with that of nifedipine, a typical L-type Ca 2+ channel blocker. The results showed that calycosin decreased aortic ring contractions induced by KCl and PHE to a similar extent, but nifedipine displayed a more potent inhibitory effect on KCl-induced contraction than on PHE-induced contraction. Auger et al observed that nifedipine (100 nmol/L) produced a more potent depression on KCl (2-100 mmol/L) concentration-response curves than on PHE (1×10 -9 -1×10 -4 mol/L) concentration-response curves [20] . Our results are in accordance with this observation, although only one concentration of vasoconstrictor was used as did Damiani et al [12] . These findings indicate that calycosin had a different action mode from nifedipine, that is, calycosin comparably blocked ROC and VOC, but nifedipine mainly blocked VOC. In order to further confirm the action characteristic of calycosin, we studied the influence of nifedipine on the effect of calycosin. The results showed that the two agents showed additive relaxant effect on KCl-induced vasoconstriction. In the combined use, the presence of nifedipine eliminated voltage-dependent Ca 2+ entry [19] , thus the enhanced vascular relaxation produced by calycosin must be a result of an additional ion channel including ROC antagonism or K + channel opening. Calycosin may act as a Ca 2+ channel blocker, which may block both voltage-dependent Ca 2+ channels and receptor-operated Ca 2+ channels; this property is different from that of dihydropyridines. However, further study is required to clarify the detailed mechanisms of calycosin on Ca 2+ channel. In conclusion, calycosin is a vasorelaxant and its action is endothelium-independent and is unrelated to intracellular Ca 2+ release. It is a noncompetitive Ca 2+ channel blocker and the effect of calycosin on Ca 2+ channel blockade may be different from that of dihydropyridines. This study demonstrated a novel pharmacological activity of calycosin and supplied a theoretic foundation for Astragali Radix application.
